Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
246 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL) - The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects - The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Peripheral T-Cell Lymphomas (PTCL) Overview 10 Therapeutics Development 11 Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 11 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 12 Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 17 Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 20 AB Science SA 20 Affimed GmbH 21 arGEN-X BV 22 Bayer AG 23 Boehringer Ingelheim GmbH 24 Celgene Corporation 25 CerRx, Inc. 26 Chipscreen Biosciences Ltd 27 CSPC Pharmaceutical Group Limited 28 Eisai Co., Ltd. 29 Genosco 30 Incyte Corporation 31 Japan Tobacco Inc. 32 Johnson & Johnson 33 Mundipharma International Ltd 34 Ono Pharmaceutical Co., Ltd. 35 Onxeo SA 36 Pfizer Inc. 37 Pharma Mar, S.A. 38 Portola Pharmaceuticals, Inc. 39 Rhizen Pharmaceuticals S.A. 40 Seattle Genetics, Inc. 41 Solasia Pharma K.K. 42 Spectrum Pharmaceuticals, Inc. 43 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 48 Assessment by Route of Administration 51 Assessment by Molecule Type 53 Drug Profiles 55 AFM-13 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 ARGX-110 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 belinostat - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 brentuximab vedotin - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 cerdulatinib - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 copanlisib hydrochloride - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 darinaparsin - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 denileukin diftitox - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 enasidenib - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 fenretinide - Drug Profile 116 Product Description 116 Mechanism Of Action 116 R&D Progress 116 forodesine hydrochloride - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 ICG-122 - Drug Profile 120 Product Description 120 Mechanism Of Action 120 R&D Progress 120 lenalidomide - Drug Profile 121 Product Description 121 Mechanism Of Action 121 R&D Progress 121 masitinib - Drug Profile 135 Product Description 135 Mechanism Of Action 135 R&D Progress 135 MEDI-570 - Drug Profile 149 Product Description 149 Mechanism Of Action 149 R&D Progress 149 mitoxantrone hydrochloride - Drug Profile 150 Product Description 150 Mechanism Of Action 150 R&D Progress 150 nivolumab - Drug Profile 152 Product Description 152 Mechanism Of Action 152 R&D Progress 152 NL-101 - Drug Profile 180 Product Description 180 Mechanism Of Action 180 R&D Progress 180 plitidepsin - Drug Profile 182 Product Description 182 Mechanism Of Action 182 R&D Progress 182 pralatrexate - Drug Profile 186 Product Description 186 Mechanism Of Action 186 R&D Progress 186 romidepsin - Drug Profile 192 Product Description 192 Mechanism Of Action 192 R&D Progress 192 RP-6530 - Drug Profile 195 Product Description 195 Mechanism Of Action 195 R&D Progress 195 ruxolitinib phosphate - Drug Profile 197 Product Description 197 Mechanism Of Action 197 R&D Progress 197 SH-7129 - Drug Profile 210 Product Description 210 Mechanism Of Action 210 R&D Progress 210 Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile 211 Product Description 211 Mechanism Of Action 211 R&D Progress 211 temsirolimus - Drug Profile 212 Product Description 212 Mechanism Of Action 212 R&D Progress 212 TGR-1202 - Drug Profile 214 Product Description 214 Mechanism Of Action 214 R&D Progress 214 tipifarnib - Drug Profile 221 Product Description 221 Mechanism Of Action 221 R&D Progress 221 tucidinostat - Drug Profile 224 Product Description 224 Mechanism Of Action 224 R&D Progress 224 volasertib trihydrochloride - Drug Profile 227 Product Description 227 Mechanism Of Action 227 R&D Progress 227 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 231 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 232 Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 233 Featured News & Press Releases 233 Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation 233 Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma 233 Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma 234 Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor 234 Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma 235 Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 235 Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 236 Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 238 Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 239 Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 240 Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 241 May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 241 Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China 243 Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 243 Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation 244 Appendix 245 Methodology 245 Coverage 245 Secondary Research 245 Primary Research 245 Expert Panel Validation 245 Contact Us 245 Disclaimer 246
List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Development by Companies, H2 2016 (Contd..1) 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Development by Companies, H2 2016 (Contd..2) 19 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H2 2016 20 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed GmbH , H2 2016 21 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by arGEN-X BV, H2 2016 22 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2016 23 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 24 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2016 25 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H2 2016 26 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 27 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 28 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2016 29 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Genosco, H2 2016 30 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2016 31 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Japan Tobacco Inc., H2 2016 32 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H2 2016 33 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H2 2016 34 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 35 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H2 2016 36 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H2 2016 37 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pharma Mar, S.A., H2 2016 38 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 39 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 40 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H2 2016 41 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H2 2016 42 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 43 Assessment by Monotherapy Products, H2 2016 44 Number of Products by Stage and Target, H2 2016 46 Number of Products by Stage and Mechanism of Action, H2 2016 49 Number of Products by Stage and Route of Administration, H2 2016 52 Number of Products by Stage and Molecule Type, H2 2016 54 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2016 231 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2016 232
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
